TY  - JOUR
AU  - Perez-Garcia, Jose Manuel
AU  - Vaz Batista, Marta
AU  - Cortez, Patricia
AU  - Ruiz-Borrego, Manuel
AU  - Cejalvo, Juan Miguel
AU  - de la Haba-Rodriguez, Juan
AU  - Garrigos, Laia
AU  - Racca, Fabricio
AU  - Servitja, Sonia
AU  - Blanch, Salvador
AU  - Gion, Maria
AU  - Nave, Monica
AU  - Fernandez-Abad, Maria
AU  - Martinez-Bueno, Alejandro
AU  - Llombart-Cussac, Antonio
AU  - Sampayo-Cordero, Miguel
AU  - Malfettone, Andrea
AU  - Cortes, Javier
AU  - Braga, Sofia
PY  - 2023
DO  - 10.1093/neuonc/noac144
UR  - http://hdl.handle.net/10668/19821
T2  - Neuro-oncology
AB  - Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BMs). DEBBRAH aims to...
LA  - en
PB  - Oxford University Press
KW  - HER2-positive
KW  - T-DXd
KW  - Advanced breast cancer
KW  - Brain metastases
KW  - Trastuzumab deruxtecan
KW  - Humans
KW  - Female
KW  - Breast neoplasms
KW  - Quality of life
KW  - Receptor, ErbB-2
KW  - Antibodies, monoclonal, humanized
KW  - Trastuzumab
KW  - Camptothecin
KW  - Central nervous system
TI  - Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial.
TY  - research article
VL  - 25
ER  -